Human Genetics Market Research Report Information by Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment), by Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

2.1 DEFINITION 15

2.2 SCOPE OF THE STUDY 15

2.3 RESEARCH OBJECTIVE 15

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 21

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 23

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS 25

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 GROWING ADOPTION OF GENETIC TESTING 26

4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER 26

4.3 RESTRAINTS 27

4.3.1 HIGH COST OF GENETIC TESTING 27

4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS 27

4.4 OPPORTUNITY 28

4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES MONITORING 30

5.2 PORTER'S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET 32

5.3.1 IMPACT ON SUPPLY CHAIN 32

5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES 33

5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION 34

6.1 OVERVIEW 34

6.2 WELLNESS & E-COMMERCE 35

6.3 PREVENTIVE MEDICINE 35

6.4 DIAGNOSTIC & TREATMENT 36

7 GLOBAL HUMAN GENETICS MARKET, BY TEST 42

7.1 OVERVIEW 42

7.2 NIPT 43

7.3 CARRIER TESTING 44

7.4 PHARMACOGENOMIC TESTING 45

7.5 KARYOTYPE TESTING 46

7.6 THROMBOPHILIA TESTING 47

7.7 SEPTIN 9 BIOMARKER TESTING 48

7.8 NGS 49

7.9 OTHERS 51

8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY 52

8.1 OVERVIEW 52

8.1.1 US 53

8.1.2 CANADA 55

8.1.3 UK 57

8.1.4 GERMANY 59

8.1.5 SPAIN 61

8.1.6 JAPAN 63

8.1.7 OTHERS 65

9 COMPETITIVE LANDSCAPE 67

9.1 OVERVIEW 67

9.2 COMPETITIVE BENCHMARKING 68

9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET 69

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET 70

9.5 KEY DEVELOPMENT ANALYSIS 71

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 71

9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 71

9.6.2 MERGER &ACQUISITION 71

9.6.3 EXPANSION 72

9.7 FINANCIAL MATRIX 72

9.7.1 SALES (USD MILLION), 2020 72

10 COMPANY PROFILES 73

10.1 MYRIAD GENETICS, INC. 73

10.1.1 COMPANY OVERVIEW 73

10.1.2 FINANCIAL OVERVIEW 74

10.1.3 PRODUCT/SERVICE OFFERED 75

10.1.4 KEY DEVELOPMENTS 75

10.1.5 SWOT ANALYSIS 76

10.1.6 KEY STRATEGIES 76

10.2 SYNLAB GROUP 77

10.2.1 COMPANY OVERVIEW 77

10.2.2 FINANCIAL OVERVIEW 77

10.2.3 PRODUCT/SERVICE OFFERED 78

10.2.4 KEY DEVELOPMENTS 78

10.2.5 SWOT ANALYSIS 79

10.2.6 KEY STRATEGIES 79

10.3 EUROFINS MEGALAB S.A. 80

10.3.1 COMPANY OVERVIEWS 80

10.3.2 FINANCIAL OVERVIEW 80

10.3.3 PRODUCT/SERVICE OFFERED 81

10.3.4 KEY DEVELOPMENTS 81

10.3.5 SWOT ANALYSIS 81

10.3.6 KEY STRATEGIES 82

10.4 BIOMARKER TECHNOLOGIES. 83

10.4.1 COMPANY OVERVIEW 83

10.4.2 FINANCIAL OVERVIEW 83

10.4.3 PRODUCT/SERVICE OFFERED 83

10.4.4 KEY DEVELOPMENTS 83

10.4.5 SWOT ANALYSIS 84

10.4.6 KEY STRATEGIES 84

10.5 ECHEVARNE LABORATORY 85

10.5.1 COMPANY OVERVIEW 85

10.5.2 FINANCIAL OVERVIEW 85

10.5.3 PRODUCT/SERVICE OFFERED 85

10.5.4 KEY DEVELOPMENTS 85

10.5.5 SWOT ANALYSIS 86

10.5.6 KEY STRATEGIES 86

10.6 ELABSCIENCE BIOTECHNOLOGY INC. 87

10.6.1 COMPANY OVERVIEW 87

10.6.2 FINANCIAL OVERVIEW 87

10.6.3 PRODUCT/SERVICE OFFERED 87

10.6.4 KEY DEVELOPMENTS 87

10.6.5 SWOT ANALYSIS 88

10.6.6 KEY STRATEGIES 88

10.7 NIMGENETICS 89

10.7.1 COMPANY OVERVIEW 89

10.7.2 FINANCIAL OVERVIEW 89

10.7.3 PRODUCT/SERVICE OFFERED 89

10.7.4 KEY DEVELOPMENTS 90

10.7.5 SWOT ANALYSIS 90

10.7.6 KEY STRATEGIES 90

10.8 SISTEMAS GENÓMICOS 91

10.8.1 COMPANY OVERVIEW 91

10.8.2 FINANCIAL OVERVIEW 91

10.8.3 PRODUCTS/SERVICES OFFERED 91

10.8.4 KEY DEVELOPMENTS 91

10.8.5 SWOT ANALYSIS 92

10.8.6 KEY STRATEGIES 92

10.9 FULLGENOMICS 93

10.9.1 COMPANY OVERVIEW 93

10.9.2 FINANCIAL OVERVIEW 93

10.9.3 PRODUCTS/SERVICES OFFERED 93

10.9.4 KEY DEVELOPMENTS 93

10.9.5 SWOT ANALYSIS 94

10.9.6 KEY STRATEGIES 94

10.10 GENINCODE 95

10.10.1 COMPANY OVERVIEW 95

10.10.2 FINANCIAL OVERVIEW 95

10.10.3 PRODUCTS/SERVICES OFFERED 95

10.10.4 KEY DEVELOPMENTS 95

10.10.5 SWOT ANALYSIS 96

10.10.6 KEY STRATEGIES 96

10.11 ATRYS HEALTH 97

10.11.1 COMPANY OVERVIEW 97

10.11.2 FINANCIAL OVERVIEW 97

10.11.3 PRODUCTS/SERVICES OFFERED 97

10.11.4 KEY DEVELOPMENTS 97

10.11.5 SWOT ANALYSIS 98

10.11.6 KEY STRATEGIES 98

10.12 GENYCA 99

10.12.1 COMPANY OVERVIEW 99

10.12.2 FINANCIAL OVERVIEW 99

10.12.3 PRODUCTS/SERVICES OFFERED 99

10.12.4 KEY DEVELOPMENTS 99

10.12.5 SWOT ANALYSIS 100

10.12.6 KEY STRATEGIES 100

10.13 IGENOMIX 101

10.13.1 COMPANY OVERVIEW 101

10.13.2 FINANCIAL OVERVIEW 101

10.13.3 PRODUCTS/SERVICES OFFERED 101

10.13.4 KEY DEVELOPMENTS 101

10.13.5 SWOT ANALYSIS 102

10.13.6 KEY STRATEGIES 102

10.14 GENOLÓGICA 103

10.14.1 COMPANY OVERVIEW 103

10.14.2 FINANCIAL OVERVIEW 103

10.14.3 PRODUCTS/SERVICES OFFERED 103

10.14.4 KEY DEVELOPMENTS 103

10.14.5 SWOT ANALYSIS 104

10.14.6 KEY STRATEGIES 104

10.15 BODE CELLMARK FORENSICS, INC. 105

10.15.1 COMPANY OVERVIEW 105

10.15.2 FINANCIAL OVERVIEW 105

10.15.3 PRODUCTS/SERVICES OFFERED 105

10.15.4 KEY DEVELOPMENTS 105

10.15.5 SWOT ANALYSIS 106

10.15.6 KEY STRATEGIES 106

11 APPENDIX 107

11.1 REFERENCES 107

11.2 RELATED REPORTS 107

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

TABLE 3 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 34

TABLE 4 GLOBAL HUMAN GENETICS MARKET FOR WELLNESS & E-COMMERCE, BY COUNTRY, 2018–2027 (USD MILLION) 35

TABLE 5 GLOBAL HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2018–2027 (USD MILLION) 36

TABLE 6 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY COUNTRY, 2018–2027 (USD MILLION) 37

TABLE 7 GLOBAL HUMAN GENETICS MARKET FOR APPLICATION, BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 37

TABLE 8 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38

TABLE 9 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38

TABLE 10 GLOBAL HUMAN GENETICS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 39

TABLE 11 GLOBAL HUMAN GENETICS MARKET FOR ASSISTED REPRODUCTION, BY COUNTRY, 2018–2027 (USD MILLION) 39

TABLE 12 GLOBAL HUMAN GENETICS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 40

TABLE 13 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 40

TABLE 14 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 40

TABLE 15 GLOBAL HUMAN GENETICS MARKET FOR NEUROPEDIATRIC, BY COUNTRY, 2018–2027 (USD MILLION) 41

TABLE 16 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 41

TABLE 17 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 43

TABLE 18 GLOBAL HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2018–2027 (USD MILLION) 44

TABLE 19 GLOBAL HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 45

TABLE 20 GLOBAL HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 46

TABLE 21 GLOBAL HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 47

TABLE 22 GLOBAL HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48

TABLE 23 GLOBAL HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48

TABLE 24 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2018–2027 (USD MILLION) 49

TABLE 25 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 49

TABLE 26 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 49

TABLE 27 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 50

TABLE 28 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51

TABLE 29 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51

TABLE 30 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY, 2018–2027 (USD MILLION) 52

TABLE 31 US: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 53

TABLE 32 US: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 53

TABLE 33 US: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 54

TABLE 34 US: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 54

TABLE 35 US: HUMAN GENETICS MARKET FOR BY NGS, BY TYPE, 2018–2027 (USD MILLION) 54

TABLE 36 CANADA: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 55

TABLE 37 CANADA: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 55

TABLE 38 CANADA: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 56

TABLE 39 CANADA: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 56

TABLE 40 CANADA: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 56

TABLE 41 UK: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 57

TABLE 42 UK: HUMAN GENETICS MARKET FOR BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 57

TABLE 43 UK: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 58

TABLE 44 UK: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 58

TABLE 45 UK: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 58

TABLE 46 GERMANY: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 59

TABLE 47 GERMANY: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 59

TABLE 48 GERMANY: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 60

TABLE 49 GERMANY: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 60

TABLE 50 GERMANY: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 60

TABLE 51 SPAIN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 61

TABLE 52 SPAIN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, FOR TYPE, 2018–2027 (USD MILLION) 61

TABLE 53 SPAIN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 62

TABLE 54 SPAIN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 62

TABLE 55 SPAIN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 62

TABLE 56 JAPAN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 63

TABLE 57 JAPAN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 63

TABLE 58 JAPAN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 64

TABLE 59 JAPAN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 64

TABLE 60 JAPAN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 64

TABLE 61 OTHERS: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 65

TABLE 62 OTHERS: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 65

TABLE 63 OTHERS: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 66

TABLE 64 OTHERS: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 66

TABLE 65 OTHERS: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 66

TABLE 66 MAJOR PLAYERS IN THE HUMAN GENETICS MARKET 67

TABLE 67 MOST ACTIVE PLAYER IN THE HUMAN GENETICS MARKET 70

TABLE 68 PRODUCT LAUNCH/PRODUCT APPROVAL 71

TABLE 69 MERGER & ACQUISITION 71

TABLE 70 EXPANSION 72

TABLE 71 MYRIAD GENETICS INC.: PRODUCT/SERVICE OFFERED 75

TABLE 72 MYRIAD GENETICS INC.: KEY DEVELOPMENTS 75

TABLE 73 SYNLAB GROUP: PRODUCT/SERVICE OFFERED 78

TABLE 74 SYNLAB GROUP: KEY DEVELOPMENTS 78

TABLE 75 EUROFINS MEGALAB S.A: PRODUCT/SERVICE OFFERED 81

TABLE 76 BIOMARKER TECHNOLOGIES: PRODUCT/SERVICE OFFERED 83

TABLE 77 ECHEVARNE LABORATORY: PRODUCT /SERVICE OFFERED 85

TABLE 78 ELABSCIENCE BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERED 87

TABLE 79 NIMGENETICS: PRODUCT/SERVICE OFFERED 89

TABLE 80 SISTEMAS GENÓMICOS: PRODUCTS OFFERED 91

TABLE 81 FULLGENOMICS: PRODUCTS/SERVICES OFFERED 93

TABLE 82 GENINCODE: PRODUCTS/SERVICES OFFERED 95

TABLE 83 GENINCODE: KEY DEVELOPMENTS 95

TABLE 84 ATRYS HEALTH: PRODUCTS/SERVICES OFFERED 97

TABLE 85 GENYCA: PRODUCTS/SERVICES OFFERED 99

TABLE 86 IGENOMIX: PRODUCTS/SERVICES OFFERED 101

TABLE 87 IGENOMIX: KEY DEVELOPMENTS 101

TABLE 88 GENOLOGICA: PRODUCTS/SERVICES OFFERED 103

TABLE 89 BODE CELLMARK FORENSICS, INC.: PRODUCTS/SERVICES OFFERED 105

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL HUMAN GENETICS MARKET 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22

FIGURE 4 MARKET DYNAMICS: GLOBAL HUMAN GENETICS MARKET 25

FIGURE 5 DRIVER IMPACT ANALYSIS 27

FIGURE 6 RESTRAINT IMPACT ANALYSIS 28

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HUMAN GENETICS MARKET 29

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL HUMAN GENETICS MARKET 31

FIGURE 9 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 34

FIGURE 10 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2020 AND 2027 (USD MILLION) 42

FIGURE 11 GLOBAL HUMAN GENETICS MARKET SHARE (%), BY COUNTRY, 2020 52

FIGURE 12 BENCHMARKING OF MAJOR COMPETITORS 68

FIGURE 13 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE HUMAN GENETICS MARKET 69

FIGURE 14 HUMAN GENETICS MARKET: COMPETITIVE LANDSCAPE 71

FIGURE 15 SALES (USD MILLION), 2020 72

FIGURE 16 MYRIAD GENETICS INC.: FINANCIAL OVERVIEW SNAPSHOT 74

FIGURE 17 MYRIAD GENETICS INC.: SWOT ANALYSIS 76

FIGURE 18 SYNLAB GROUP: FINANCIAL OVERVIEW SNAPSHOT 77

FIGURE 19 SYNLAB GROUP: SWOT ANALYSIS 79

FIGURE 20 EUROFINS MEGALAB S.A.: FINANCIAL OVERVIEW SNAPSHOT 80

FIGURE 21 EUROFINS MEGALAB S.A: SWOT ANALYSIS 81

FIGURE 22 BIOMARKER TECHNOLOGIES: SWOT ANALYSIS 84

FIGURE 23 ECHEVARNE LABORATORY: SWOT ANALYSIS 86

FIGURE 24 ELABSCIENCE BIOTECHNOLOGY INC.: SWOT ANALYSIS 88

FIGURE 25 NIMGENETICS: SWOT ANALYSIS 90

FIGURE 26 SISTEMAS GENÓMICOS: SWOT ANALYSIS 92

FIGURE 27 FULLGENOMICS: SWOT ANALYSIS 94

FIGURE 28 GENINCODE: SWOT ANALYSIS 96

FIGURE 29 ATRYS HEALTH: SWOT ANALYSIS 98

FIGURE 30 GENYCA: SWOT ANALYSIS 100

FIGURE 31 IGENOMIX: SWOT ANALYSIS 102

FIGURE 32 GENOLOGICA: SWOT ANALYSIS 104

FIGURE 33 BODE CELLMARK FORENSICS, INC.: SWOT ANALYSIS 106